S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

$106.62
+0.92 (+0.87 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$105.85
Now: $106.62
$109.05
50-Day Range
$96.10
MA: $112.55
$137.56
52-Week Range
$90.14
Now: $106.62
$196.00
Volume580,573 shs
Average Volume540,620 shs
Market Capitalization$3.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.16
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.74 million
Book Value$22.23 per share

Profitability

Net Income$-79,880,000.00

Miscellaneous

Employees791
Market Cap$3.29 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.


GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) posted its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping analysts' consensus estimates of ($2.40) by $1.14. The biopharmaceutical company had revenue of $3.46 million for the quarter, compared to the consensus estimate of $2 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.04% and a negative net margin of 26.80%. View GW Pharmaceuticals PLC-'s Earnings History.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for GW Pharmaceuticals PLC-.

What price target have analysts set for GWPH?

13 brokerages have issued 1-year price objectives for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $170.00 to $238.00. On average, they anticipate GW Pharmaceuticals PLC-'s share price to reach $206.90 in the next year. This suggests a possible upside of 94.1% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

What is the consensus analysts' recommendation for GW Pharmaceuticals PLC-?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

News coverage about GWPH stock has been trending positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for GW Pharmaceuticals PLC-.

Are investors shorting GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 5,460,000 shares, an increase of 6.2% from the November 14th total of 5,140,000 shares. Based on an average daily trading volume, of 791,900 shares, the days-to-cover ratio is presently 6.9 days. Approximately 17.8% of the shares of the company are sold short. View GW Pharmaceuticals PLC-'s Current Options Chain.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

What other stocks do shareholders of GW Pharmaceuticals PLC- own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Cronos Group (CRON), Netflix (NFLX), GW Pharmaceuticals (GWP), Zynerba Pharmaceuticals (ZYNE), Aurora Cannabis (ACB) and Cara Therapeutics (CARA).

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the folowing people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
  • Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)

Who are GW Pharmaceuticals PLC-'s major shareholders?

GW Pharmaceuticals PLC-'s stock is owned by a number of of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (2.95%), Pictet Asset Management Ltd. (0.78%), River & Mercantile Asset Management LLP (0.44%), Massachusetts Financial Services Co. MA (0.33%), Hardman Johnston Global Advisors LLC (0.19%) and California Public Employees Retirement System (0.18%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

Which major investors are selling GW Pharmaceuticals PLC- stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Squarepoint Ops LLC, Foundry Partners LLC, Tocqueville Asset Management L.P., Janney Montgomery Scott LLC, Endurant Capital Management LP, Prospera Financial Services Inc and Tower Research Capital LLC TRC. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

Which major investors are buying GW Pharmaceuticals PLC- stock?

GWPH stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., River & Mercantile Asset Management LLP, Nomura Holdings Inc., Tamarack Advisers LP, Massachusetts Financial Services Co. MA, California Public Employees Retirement System, Voloridge Investment Management LLC and GW&K Investment Management LLC. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $106.62.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $3.29 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-79,880,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  713 (Vote Outperform)
Underperform Votes:  447 (Vote Underperform)
Total Votes:  1,160
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel